Clinical Trial Update: The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511) [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating treatment-induced changes in GERD-related symptoms (BY1023/NL511) conducted by Takeda has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease
• Non-erosive Reflux Disease

Drugs mentioned

• BY1023/NL511

Snippet

Sponsor: Takeda | Conditions: Gastroesophageal Reflux Disease, Non-erosive Reflux Disease | Phase 4 | Status: TERMINATED